Recently, Porton Advanced proudly announced that its Umbilical Cord-Derived Mesenchymal Stem Cell (UC-MSCs) Cell Bank for exosome ...
Introduction - On June 29, 2026, the U.S. Department of the Treasury’s Office of Foreign Assets Control, commonly known as ...
Shoko Co., Ltd. (Head Office: Minato-ku, Tokyo; President & CEO: Kentaro Watanabe; hereinafter “Shoko”), a comprehensive commodity tradin ...
Indian companies filed 184 Type II DMFs with the US FDA in Q1 2026 against China's 149, reinforcing the country's leadership ...
Cellares, the first Integrated Development and Manufacturing Organization (IDMO), today announced its acceptance into the U.S ...
Strategic collaboration at Sanford, North Carolina facility, currently under construction, to optimize cGMP validation, accelerate time-to-market for complex biologics, and shore up U.S. medicine ...
FDA names companies domestic drug manufacturing pilot participants to enhance early regulatory engagement and streamline review processes.
SEATTLE--(BUSINESS WIRE)--Pluristyx, a leading provider of innovative, unmodified, and gene-edited induced pluripotent stem cell (iPSC) lines, submitted a Type II Drug Master File (DMF) to the U.S.
OpenAI, the company behind ChatGPT, has joined the race between the three tech giants set to list in 2026, each tipped for a landmark initial public offering (IPO). One week after Anthropic filed its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results